Literature DB >> 27047691

Serotyping and Antimicrobial Susceptibility Pattern of Escherichia coli Isolates from Urinary Tract Infections in Pediatric Population in a Tertiary Care Hospital.

Shweta Sharma1, Nirmaljit Kaur1, Shalini Malhotra1, Preeti Madan1, Wasim Ahmad1, Charoo Hans1.   

Abstract

Urinary tract infections (UTIs) in pediatric population are associated with high morbidity and long term complications. In recent years, there is increased prevalence of Escherichia coli (E. coli) strains producing extended spectrum β-lactamase, Amp C, and Metallo β-lactamase, making the clinical management even more difficult. This study was aimed to detect the serotypes and to determine antimicrobial susceptibility profile of E. coli isolates from urine samples of children <10 yrs old. A total of 75 pure E. coli strains isolated from patients with symptoms of UTI and colony count ≥10(5) organisms/mL were included in the study. Antibiotic sensitivity pattern showed maximum resistance to nalidixic acid (98.7%), followed by ampicillin (97.3%), amoxi-clavulanate (96%), and fluoroquinolones (92%) while most of the isolates were found sensitive to piperacillin-tazobactam (13.3%), nitrofurantoin (5.3%), and meropenem (1.3%). 48% of the strains were ESBL producer (extended spectrum beta lactamase). 44% strains were typable withantisera used in our study and the most common serogroup was O6 (33.3%) followed by O1 (15.1%) and O15 (15.1%). To conclude, judicious use of antibiotics according to hospital antibiotic policy and infection control measures should be implemented to prevent spread of multidrug resistant organisms.

Entities:  

Year:  2016        PMID: 27047691      PMCID: PMC4800102          DOI: 10.1155/2016/2548517

Source DB:  PubMed          Journal:  J Pathog        ISSN: 2090-3057


1. Introduction

Urinary tract infections (UTIs) are one of the most common infections encountered in the clinical practice, and in pediatric population it is associated with high morbidity and long term complications like renal scarring, hypertension, and chronic renal failure [1]. Early diagnosis, proper investigation, adequate therapy, and prolonged careful follow-up in children with UTI will decrease chronic renal failure in adults. UTI is mainly associated with members of the Enterobacteriaceae family and Escherichia coli (E. coli) are the most predominant pathogen causing UTIs [2]. E. coli that are associated with UTI are commonly named uropathogenic isolates, although there is evidence that different pathotypes may be related to UTI; however, uropathogenic E. coli (UPEC) is responsible for approximately 90% of all UTIs [3]. Uropathogenic E. coli (UPEC) possess virulence factors which help them to colonize the periurethral area, enter urinary tract, and cause retrograde infection. E. coli strains are normally identified by serological typing of their H (flagellar), O (lipopolysaccharide), and, in some cases, K (capsular) surface antigens. Since, 176 O-serogroups had been described for E. coli [3]. In UPEC, the O-serogroups are related to the virulence factor profile of each strain. Previous studies reported that O1, O2, O4, O6, O7, O8, O15, O16, O18, O21, O22, O25, O75, and O83 serogroups are preferentially associated with UPEC strains [4, 5]. Each serotype of E. coli has an important role in clinical presentation of UTI, and the prevalence of different serotypes varies in different regions. In recent years, there has been an increase in the resistance to cephalosporins, fluoroquinolones, and trimethoprim among UTI cases, which is a growing cause of concern. In hospitalized patients, there is increased prevalence of E. coli strains producing extended spectrum β-lactamase, Amp C, and Metallo-β-lactamase, making the clinical management even more difficult [6, 7]. Also clinicians must be aware of the susceptibility patterns of UPEC strains in their specific geographical populations to optimize the use of empirical antibiotic therapy for UTIs. This study was aimed to detect the serotypes and to determine antimicrobial susceptibility profile of E. coli isolates from urine samples of children less than 10 yrs old.

2. Materials and Methods

This cross-sectional observational study was conducted in the Department of Microbiology in a tertiary care centre, New Delhi. The samples were collected from children <10 yrs admitted in pediatric ward, ICU (intensive care unit), and also from children whoattended OPD (out-patient department) with symptoms of UTI. Informed consent was taken from all patients included in the study. Urine specimen was obtained through catheterization, suprapubic aspiration (SPA), or midstream urine after thorough cleaning of the perineal region [8, 9]. The freshly collected urine samples were inoculated on 5% sheep blood agar and MacConkey (MCA) agar and then incubated at 37°C for 24 hrs. Culture plates with a growth of single morphotype of E. coli having colony counts ≥105 CFU/mL were considered significant. A total of 75 E. coli strains isolated over a period of one year from January 2014 to December 2014 were included in the study. E. coli isolates were identified on the basis of colony morphology and various biochemicals like motility, oxidase, sugars, indole, methyl red, Voges Proskauer, citrate, urease, triple sugar iron agar, lysine and ornithine decarboxylase and arginine dihydrolase, and so forth [10]. Also the isolates were confirmed in automated system, that is, Microscan WalkAway 40 plus system. All the isolates were tested for antimicrobial susceptibility by Kirby Bauer's disc diffusion method and zone diameters were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [11]. The antibiotics tested were ampicillin (10 μg), gentamicin (10 μg), amikacin (30 μg), nalidixic acid (30 μg), nitrofurantoin (300 μg), cefotaxime (30 μg), ceftazidime (30 μg), amoxy-clavulanic acid (20/10 μg), piperacillin-tazobactam (100/10 μg), meropenem (10 μg), and cotrimoxazole (1.25/23.75 μg) (Hi-Media Pvt. Laboratories, Bombay, India). Quality control strain E. coli ATCC 25922 was used to validate the results of the antimicrobial discs. ESBL production was determined by using phenotypic confirmatory test: antibiotic disc of ceftazidime 30 μg and ceftazidime-clavulanic acid 30/10 μg and also cefotaxime 30 μg and cefotaxime-clavulanic acid 30/10 μg (Hi-Media) were placed on inoculated Mueller-Hinton Agar (MHA) media 30 mm apart from centre to centre and incubated at 37°C for 16–18 h. The zone of inhibition was recorded and difference in zone size of 5 mm or more for either antimicrobial agents tested in combination with clavulanic acid versus its zone when tested alone were considered ESBL [11]. Serotyping of E. coli strains was performed using 7 different monoclonal E. coli (EPEC) test sera (Statens Serum Institute) according to manufacturer's recommendations. Polyvalent antisera used in our study included O1, O2, O4, O6, O7, O15, and O75 serotypes. The isolate giving positive reaction with polyvalent antisera was retested with individual antisera. Colony of E. coli was inoculated in Brain Heart Infusion (BHI) broth and incubated overnight at 37°C. After boiling for 1 hr, 80 μL of supernatant was mixed with equal quantity of antiserum in a microtitre plate and incubated overnight. Carpet formation was taken as positive reaction and button formation as negative reaction [12]. All the data were entered in the Microsoft excel sheet and processed for statistical analysis to calculate various percentages.

3. Results

Out of seventy-five E. coli strains isolated from children, male : female ratio was found to be 1.2 : 1 with 54.7% of the patients being males. 66.7% of the isolates were derived from admitted patients while 33.3% of the patients came to OPD with symptoms of UTI. 54.7% of the isolates were from ward patients followed up by OPD (33.3%) and ICU (12%) (Table 1). Admitted patients developed UTI after admission in the hospital and were having hospital acquired UTI with risk factors like catheterization (72%), antibiotic use (96%), and immunosuppression (22%). OPD patients came with symptoms of UTI and were labelled as community acquired UTI with no risk factors. Antibiotic sensitivity pattern of uropathogenic E. coli showed maximum resistance to nalidixic acid (98.7%), followed by ampicillin (97.3%), amoxi-clavulanate (96%), and trimethoprim-sulfamethoxazole (84%) while most of the isolates were found sensitive to piperacillin-tazobactam (13.3%), nitrofurantoin (5.3%), and meropenem (1.3%). 36 (48%) of the strains were ESBL producer (extended spectrum beta lactamase) (Table 2). Majority of the isolates (90%) were multidrug resistant (≥3 classes of antimicrobials) and one strain was found resistant to carbapenem group, while none of the strains were sensitive to all the antibiotics tested (Table 2). A total of 33 (44%) strains were typable with antisera used in our study while 42 (56%) were nontypable. The most common serogroup was O6 (33.3%) followed by O1 (15.1%) and O15 (15.1%) as shown in Table 3. The antimicrobial susceptibility pattern was similar among typable strains and nontypable strains as shown in Table 2.
Table 1

Age and area wise distribution of E. coli among children (<10 yrs).

Age groupsTotalMaleFemale OPDWard ∗∗ICU
0-1 yrs14 (18.7%)104482
1–5 yrs29 (38.7%)19109146
5–10 yrs32 (42.7%)122012191
Total 75 41 (54.7%) 34 (45.3%) 25 (33.3%) 41 (54.7%) 9 (12%)

OPD: out-patient department, ICU: intensive care unit.

Table 2

Antimicrobial resistance profile among E. coli isolates.

E. coli (n = 75)Resistance (%)Typable strains (n = 33)Nontypable strains (n = 42)
Ampicillin 73 (97.3%)33 (100%)40 (95.2%)
Gentamicin 35 (46.7%)15 (45.4%)20 (47.6%)
Amikacin 12 (16%)6 (18.2%)6 (14.3%)
Amoxicillin/clavulanate72 (96%)32 (97%)40 (95.2%)
Trimethoprim-sulfamethoxazole63 (84%)26 (78.8%)37 (88.1%)
Nitrofurantoin4 (5.3%)2 (6%)2 (4.7%)
Nalidixic acid74 (98.7%)33 (100%)41 (97.6%)
Cefotaxime61 (81.3%)30 (90.9%)31 (73.8%)
Piperacillin/tazobactam10 (13.3%)5 (15.1%)5 (11.9%)
Meropenem 1 (1.3%)1 (3%)0 (0%)
ESBL 36 (48%)19 (57.6%)17 (40.5%)

ESBL: extended spectrum beta lactamase.

Table 3

Frequency of E. coli serogroups in children with urinary tract infection.

SerogroupNumber
O15 (15.1%)
O23 (9.1%)
O43 (9.1%)
O611 (33.3%)
O72 (6.1%)
O155 (15.1%)
O754 (12.1%)
Total typable33 (44%)
Total nontypable42 (56%)

4. Discussion

Our study describes the distribution, antibiotic susceptibility pattern, and serogroups of E. coli isolated from children < 10 yrs with symptoms of UTI and colony count more than 105 organisms/mL in our hospital. There was an overall male preponderance (54.7%) which is in accordance with other studies [1, 13]; however other studies suggest higher prevalence of UTI among females compared to males [14, 15]. During the first year of life, boys have a higher incidence of UTI of about 2.7% compared to girls (0.7%) while in all other age groups, girls are more prone to developing UTI. In our study, males were more commonly involved till 5 yrs of age, while females are more common between 5 and 10 yrs of age [9]. E. coli have several factors responsible for their attachment to the uroepithelium like adhesin, pili, fimbriae, and P1-blood group phenotype receptor [16]. Antibiotic resistance has increased over years, varies from country to country, and is a major clinical problem in treating infections caused by these microorganisms. Maximum isolates (85–90%) showed high resistance to cefotaxime, norfloxacin, nalidixic acid, cotrimoxazole, and amoxy-clavulanic acid while resistance to gentamicin and amikacin was found to be 46.7% and 16%, respectively. Amikacin has to be administered parenterally and it is nephrotoxic. However, isolates were found more sensitive to nitrofurantoin (5.3%) and piperacillin-tazobactam (13.3%). These findings were in accordance with other studies [17, 18]. Increased resistance might be due to widespread, inappropriate use of antibiotics and production of extended spectrum beta lactamases in these isolates [18, 19]. In our study, 48% of E. coli strains were found to produce ESBL which is consistent with other Indian studies [17, 20]. Carbapenems are the drug of choice for isolates producing ESBL as carbapenem group is highly stable against β-lactamase. In the present study, all the isolates except one were found to be sensitive to carbapenems (meropenem). With increasing resistance among most antibiotics, a urine culture with sensitivity pattern of isolates should be obtained before starting treatment. Only limited O-serogroups of E. coli like O1, O2, O4, O6, O7, O15, O21, O22, O25, O75, O83, and so forth have been associated with UTI and their prevalence varies from place to place and time to time. In our study, 44% of E. coli isolates were found to react with polyvalent O-serogroups and the most common O-serogroup was O6 (33.3%), followed by O1 (15.1%), O15 (15.1%), and O75 (12.1%). Similarly, O6 was the most common serotype isolated in E. coli causing UTI in other studies [12, 21]. However, few studies suggest O1 as the most common serotype among UTI isolates, which is the second most common serotype among typable strains in our study [22]. It has been reported that strains belonging to O6, O15, and O75 serogroups possess specific virulence factors which confer them special invasive ability [23]. 56% percent of the E. coli isolates did not type with above used sera, suggesting that large proportion of UTIs in the community is caused by other serotypes also. This underscores the need for further studies to establish the origins and transmission of these strains. The antimicrobial resistance in typable strains was found to be similar to nontypable strains showing high level of resistance to cefotaxime, norfloxacin, nalidixic acid, cotrimoxazole, and amoxy-clavulanic acid and low level of resistance to nitrofurantoin (5.3%), piperacillin-tazobactam (13.3%), and meropenem (3%) among typable strains. Out of 33 E. coli isolates which reacted with polyvalent serogroups, 19 (57.6%) were ESBL producers but relation between these serotypes and ESBL production was not found to be significant. To conclude, judicious use of antibiotics according to hospital antibiotic policy should be done to prevent emergence of resistant organisms. Infection control measures should be properly implemented to prevent spread of ESBL and multidrug resistant strains in the hospital. However, only limited serotypes were tested in our study and further studies with large number of samples and complete serotyping of E. coli are needed.
  17 in total

Review 1.  Urinary tract infections: disease panorama and challenges.

Authors:  W E Stamm; S R Norrby
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

2.  The prevalence of O serogroups of Escherichia coli strains causing acute urinary tract infection in children in Iran.

Authors:  Fatemeh Emamghorashi; Shohreh Farshad; Mehdi Kalani; Shadokht Rajabi; Maryam Hoseini
Journal:  Saudi J Kidney Dis Transpl       Date:  2011-05

Review 3.  Diagnosis and management of pediatric urinary tract infections.

Authors:  Joseph J Zorc; Darcie A Kiddoo; Kathy N Shaw
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Frequency and susceptibility profile of pathogens causing urinary tract infections at a tertiary care hospital in western Nepal.

Authors:  R N Das; T S Chandrashekhar; H S Joshi; M Gurung; N Shrestha; P G Shivananda
Journal:  Singapore Med J       Date:  2006-04       Impact factor: 1.858

Review 5.  Pediatric urinary tract infections.

Authors:  Steven L Chang; Linda D Shortliffe
Journal:  Pediatr Clin North Am       Date:  2006-06       Impact factor: 3.278

6.  Pediatric urinary tract infections in a tertiary care center from north India.

Authors:  Neelam Taneja; Shiv Sekhar Chatterjee; Meenakshi Singh; Surjit Singh; Meera Sharma
Journal:  Indian J Med Res       Date:  2010-01       Impact factor: 2.375

7.  Uropathogenic Escherichia coli (UPEC) strains may carry virulence properties of diarrhoeagenic E. coli.

Authors:  Cecilia M Abe; Fábia A Salvador; Ivan N Falsetti; Mônica A M Vieira; Jorge Blanco; Jesús E Blanco; Miguel Blanco; Antônia M O Machado; Waldir P Elias; Rodrigo T Hernandes; Tânia A T Gomes
Journal:  FEMS Immunol Med Microbiol       Date:  2008-04

Review 8.  Origins and virulence mechanisms of uropathogenic Escherichia coli.

Authors:  Travis J Wiles; Richard R Kulesus; Matthew A Mulvey
Journal:  Exp Mol Pathol       Date:  2008-04-08       Impact factor: 3.362

9.  Correlation of P blood group, vesicoureteral reflux, and bacterial attachment in patients with recurrent pyelonephritis.

Authors:  H Lomberg; L A Hanson; B Jacobsson; U Jodal; H Leffler; C S Edén
Journal:  N Engl J Med       Date:  1983-05-19       Impact factor: 91.245

10.  Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic Escherichia coli from a semi urban locality in India.

Authors:  Savita Jadhav; Arif Hussain; Savita Devi; Ashutosh Kumar; Sana Parveen; Nageshwari Gandham; Lothar H Wieler; Christa Ewers; Niyaz Ahmed
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

View more
  9 in total

1.  Virulence factors analysis and antibiotic resistance of uropathogenic Escherichia coli isolated from patients in northeast of Iran.

Authors:  Mahdis Ghavidel; Tahere Gholamhosseini-Moghadam; Kimiya Nourian; Kiarash Ghazvini
Journal:  Iran J Microbiol       Date:  2020-06

2.  Identification of extended spectrum beta lactamases, AmpC and carbapenemase production among isolates of Escherichia coli in North Indian tertiary care centre.

Authors:  Uma Chaudhary; Shipra Agarwal; Kausalya Raghuraman
Journal:  Avicenna J Med       Date:  2018 Apr-Jun

3.  Antimicrobial susceptibility, risk factors and prevalence of bla cefotaximase, temoneira, and sulfhydryl variable genes among Escherichia coli in community-acquired pediatric urinary tract infection.

Authors:  Kallyadan V Nisha; Shetty A Veena; Shenoy D Rathika; Shenoy M Vijaya; Shetty K Avinash
Journal:  J Lab Physicians       Date:  2017 Jul-Sep

4.  High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal.

Authors:  Narayan Prasad Parajuli; Pooja Maharjan; Hridaya Parajuli; Govardhan Joshi; Deliya Paudel; Sujan Sayami; Puspa Raj Khanal
Journal:  Antimicrob Resist Infect Control       Date:  2017-01-11       Impact factor: 4.887

5.  Detection, characterization, and antibiogram of extended-spectrum beta-lactamase Escherichia coli isolated from bovine milk samples in West Bengal, India.

Authors:  Kunal Batabyal; Abhiroop Banerjee; Susmita Pal; Samir Dey; Siddhartha Narayan Joardar; Indranil Samanta; Devi Prasad Isore; Abhishek Dharm Singh
Journal:  Vet World       Date:  2018-10-16

6.  Escherichia coli Strains Responsible for Cystitis in Female Pediatric Patients with Normal and Abnormal Urinary Tracts Have Different Virulence Profiles.

Authors:  Marta de Oliveira Domingos; Silvio Marciano da Silva Junior; Wagner Milanello; Shirley Sizue Nakamura Nakano; Marcia Regina Franzolin; Luis Fernando Dos Santos; Kamila Oliveira Nunes; Vaniky Duarte Marques; Waldir P Elias; Herbert Guimarães de Sousa Silva; Bruna De Lucca Caetano; Roxane Maria Fontes Piazza
Journal:  Pathogens       Date:  2022-02-10

7.  RB49-like Bacteriophages Recognize O Antigens as One of the Alternative Primary Receptors.

Authors:  Alexandr D Efimov; Alla K Golomidova; Eugene E Kulikov; Ilya S Belalov; Pavel A Ivanov; Andrey V Letarov
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

8.  Fast and Accurate Bacterial Species Identification in Urine Specimens Using LC-MS/MS Mass Spectrometry and Machine Learning.

Authors:  Florence Roux-Dalvai; Clarisse Gotti; Mickaël Leclercq; Marie-Claude Hélie; Maurice Boissinot; Tabiwang N Arrey; Claire Dauly; Frédéric Fournier; Isabelle Kelly; Judith Marcoux; Julie Bestman-Smith; Michel G Bergeron; Arnaud Droit
Journal:  Mol Cell Proteomics       Date:  2019-10-04       Impact factor: 5.911

9.  Characterization of Plasmid-Mediated Quinolone Resistance and Serogroup Distributions of Uropathogenic Escherichia coli among Iranian Kidney Transplant Patients.

Authors:  Amin Sadeghi; Mehrdad Halaji; Amirhossein Fayyazi; Seyed Asghar Havaei
Journal:  Biomed Res Int       Date:  2020-10-27       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.